Supplementary Data from Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants

Supplementary Data from Expanding the Reach of Precision Oncology by Drugging All KRAS Mutant

Supplementary Figure 4 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 118K, LIM1215 knocked-in with a KRAS G12R mutation are also capable of paracrine protection of sensitive wild type (wt) cells and secrete higher levels of TGFalpha.</p

Supplementary Figure Legends from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 105K</p

Supplementary Figure 2 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 133K, Measurements of additional receptor ligands from conditioned media.</p

Supplementary Figure 3 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 38K, Alternative comparative presentation of results presented in Figure 3 C-F.</p

Supplementary Figure 1 from TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

PDF file - 95K, Schematic representation of conditioned medium assay (CMA).</p

Supplementary Methods, Figure Legends, Table Legends, Figures S1 - S4, Tables S1 - S5 from Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer

Supplementary Figure S1. LMNA-NTRK1 genetic rearrangement detected in patient's plasma and xeno. Supplementary Figure S2. Acquisition of mutations in the TRKA kinase domain drives secondary resistance to entrectinib in Ba/F3 TRKA WT cells. Supplementary Figure S3. NTRK1 mutations confer resistance to TRKA inhibition. Supplementary Figure S4. Homology alignment of NTRK1 p.G595 and p.G667 variants. Supplementary Table S1. NGS analysis of NTRK1 gene in patient's plasma and xeno. Supplementary Table S2. NGS analysis of patient's derived samples. Supplementary Table S3. Summary of serial ctDNA analyses. Supplementary Table S4. The p.G595R and p.G667C mutations confer resistance to multiple TRK inhibitors. Supplementary Table S5. NTRK1 p. G595R, p.G667C and LMNA-NTRK1 fusion probes for ddPCR.</p

Supplementary Figures Legends from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Legends to supplementary table, data and figures</p

Figure S5 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Supplementary Figure 5</p

Table S1 from KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Supplementary Table 1</p